BCL2 and cancer: A systematic survey and meta-analysis of the transcriptional profiles of a variety of cancers indicated that the dysregulation of Bcl-2 is a key distinguishing factor between normal and cancer cells [9]; moreover, its increased expression has been correlated with increased resistance of a variety of cancers to chemotherapy drugs, including cisplatin [10, 11].